260 related articles for article (PubMed ID: 38611066)
1. Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives.
De Gaetano V; Pallozzi M; Cerrito L; Santopaolo F; Stella L; Gasbarrini A; Ponziani FR
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611066
[TBL] [Abstract][Full Text] [Related]
2. Screening and management of portal hypertension in advanced hepatocellular carcinoma: A French practice survey.
Allaire M; Manfredi S; Lerosey L; Ganne-Carrié N; Thabut D
Clin Res Hepatol Gastroenterol; 2023 Feb; 47(2):102059. PubMed ID: 36455860
[TBL] [Abstract][Full Text] [Related]
3. Baveno VI and VII criteria are not suitable for screening for large varices or clinically significant portal hypertension in patients with hepatocellular carcinoma.
Allaire M; Campion B; Demory A; Larrey E; Wagner M; Rudler M; Roux C; Blaise L; Carrie NG; Thabut D
Aliment Pharmacol Ther; 2023 Aug; 58(3):346-356. PubMed ID: 37300315
[TBL] [Abstract][Full Text] [Related]
4. A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC.
Larrey E; Campion B; Evain M; Sultanik P; Blaise L; Giudicelli H; Wagner M; Cluzel P; Rudler M; Ganne-Carrié N; Thabut D; Allaire M
Liver Int; 2022 Dec; 42(12):2843-2854. PubMed ID: 36254617
[TBL] [Abstract][Full Text] [Related]
5. Systemic treatment for unresectable hepatocellular carcinoma.
Leowattana W; Leowattana T; Leowattana P
World J Gastroenterol; 2023 Mar; 29(10):1551-1568. PubMed ID: 36970588
[TBL] [Abstract][Full Text] [Related]
6. Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.
Cifuentes LI; Gattini D; Torres-Robles R; Gana JC
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD011561. PubMed ID: 33522602
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma.
Catalano M; Casadei-Gardini A; Vannini G; Campani C; Marra F; Mini E; Roviello G
Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1353-1365. PubMed ID: 34289756
[TBL] [Abstract][Full Text] [Related]
8. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
9. Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses….
Allaire M; Rudler M; Thabut D
Liver Int; 2021 Aug; 41(8):1734-1743. PubMed ID: 34051060
[TBL] [Abstract][Full Text] [Related]
10. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
J Hepatol; 2024 Mar; ():. PubMed ID: 38479612
[TBL] [Abstract][Full Text] [Related]
11. Portal hypertension and variceal bleeding in patients with liver cancer: Evidence gaps for prevention and management.
Allaire M; Thabut D
Hepatology; 2024 Jan; 79(1):213-223. PubMed ID: 36631021
[TBL] [Abstract][Full Text] [Related]
12. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study.
Lim J; Kim HI; Kim E; Kim J; An J; Chang S; Kim SO; Lee HC; Lee YS; Shim JH
BMC Cancer; 2021 Jan; 21(1):11. PubMed ID: 33402105
[TBL] [Abstract][Full Text] [Related]
13. Management of portal hypertension in patients treated with atezolizumab and bevacizumab for hepatocellular carcinoma.
Ollivier-Hourmand I; Allaire M; Cervoni JP;
J Hepatol; 2022 Aug; 77(2):566-567. PubMed ID: 35182660
[No Abstract] [Full Text] [Related]
14. Systemic therapy for hepatocellular carcinoma: current status and future perspectives.
Furuse J; Ueno M; Ikeda M
Jpn J Clin Oncol; 2021 Aug; 51(9):1363-1371. PubMed ID: 34258616
[TBL] [Abstract][Full Text] [Related]
15. Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma-report a case and literature review.
Lin TY; Su TH
J Formos Med Assoc; 2024 Apr; ():. PubMed ID: 38565487
[TBL] [Abstract][Full Text] [Related]
16. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
17. Two cases of rapid progression of esophageal varices after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furusawa A; Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Apr; 15(2):451-459. PubMed ID: 35179703
[TBL] [Abstract][Full Text] [Related]
18. TKIs in combination with immunotherapy for hepatocellular carcinoma.
Stefanini B; Ielasi L; Chen R; Abbati C; Tonnini M; Tovoli F; Granito A
Expert Rev Anticancer Ther; 2023 Mar; 23(3):279-291. PubMed ID: 36794716
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
[TBL] [Abstract][Full Text] [Related]
20. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease.
Perera S; Kelly D; O'Kane GM
Curr Oncol; 2020 Nov; 27(Suppl 3):S165-S172. PubMed ID: 33343210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
